COMMUNIQUÉS West-GlobeNewswire

Cynet Named Leader and Outperformer in 2026 GigaOm Radar for Extended Detection and Response (XDR)
09/04/2026
BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Cynet, the unified, AI-powered cybersecurity platform empowering organizations to focus on what matters most, has been named a Leader and Outperformer in the 2026 GigaOm Radar [...]
Biodesix Recognized as a Top Workplace for Third Consecutive Year
09/04/2026
Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture LOUISVILLE, Colo., April 09, 2026 (GLOBE NEWSWIRE) -- Biodesix is proud to announce that it has earned the [...]
USA Today Names Aledade a 2026 Top Workplace for People-First Culture
09/04/2026
National award honors Aledade’s commitment to employee engagement and its mission-driven approach to advancing value-based care BETHESDA, Md., April 09, 2026 (GLOBE NEWSWIRE) -- Aledade , a physician-led, national [...]
Erratum: Correction of press release published on April 7th, 2026
09/04/2026
The press release published on April 7 th , related to the acquisition of own shares, contained the following errors: In the third paragraph, the number of repurchased shares shall read “32,000” instead of “16,000”; In [...]
Erratum: Correction du communiqué de presse publié le 7 avril 2026
09/04/2026
Le communiqué de presse publié le 7 avril 2026, relatif à l’acquisition d’actions propres, contenait les erreurs suivantes : Au troisième paragraphe, le nombre d’actions rachetées doit être “32.000 ” au lieu de “16.000 [...]
Cloudbreak Pharma Announces Launch of Cloudbreakpharma.com to Raise Awareness of its Pipeline of Novel First-in-Class Therapeutics to Treat Serious Underserved Ophthalmic Diseases
09/04/2026
Lead candidate, CBT-001 for the treatment of pterygium, a multi-billion-dollar addressable market, is in mid-Phase 3 with initial topline data anticipated in Q3 2026 Second asset, CBT-004 for the treatment of pinguecula [...]
Fedora Pharmaceuticals Showcasing Antibiotic Candidate at 2026 European Society of Clinical Microbiology and Infectious Diseases Congress
09/04/2026
EDMONTON, Alberta , April 09, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, intends to present a full suite of preclinical findings [...]
Over 60 Million Showed They Are #MoreThanMyeloma During 2026 Myeloma Action Month
09/04/2026
Myeloma Action Month Global Campaign Celebrated Resilience, Strengthened Connections, and Inspired Hope in 96 Countries STUDIO CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- As this year’s Myeloma Action Month came to [...]
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson
09/04/2026
Vinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI [...]
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
09/04/2026
CEO Abizer Gaslightwala discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation and development acceleration Company highlights accelerated IND timeline for AKTX-101 and [...]
Tria Federal Earns Prestigious 2026 USA TODAY Top Workplaces Award
09/04/2026
ARLINGTON, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Tria Federal is proud to announce that it has earned the prestigious 2026 USA TODAY Top Workplaces award. The award honors organizations with 150 or more employees that [...]
Highridge Medical Enters Exclusive Distribution Agreement for the Waypoint GPS Enabling Technology Platform
09/04/2026
Highridge portfolio expands to include an innovative pedicle probe with real-time visual feedback. WESTMINSTER, Colo., April 09, 2026 (GLOBE NEWSWIRE) -- Highridge Medical, a leading privately held global spine company [...]
Beech Acres Parenting Center Wins Seven National Top Workplaces Awards, Including Nonprofit Industry and Culture Excellence Awards
09/04/2026
CINCINNATI, April 09, 2026 (GLOBE NEWSWIRE) -- Beech Acres Parenting Center, where highly engaged and supported staff inspire and equip today’s parents, families and communities to raise capable, resilient and [...]
Cerevance to Present Positive Phase 2 Solengepras Data in Parkinson’s Disease at the American Academy of Neurology 2026 Annual Meeting
09/04/2026
Solengepras, a once-daily, oral, non-dopaminergic GPR6 inhibitor, demonstrated meaningful reductions in daily OFF time and improvements in sleep-related symptoms across two Phase 2 trials Meeting presentations highlight [...]
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
09/04/2026
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will [...]
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
09/04/2026
Important ophthalmic treatment expected to be an important growth driver for Amneal’s Affordable Medicines segment BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “ [...]
The Growing Connection Between Microplastics and the Human Heart
09/04/2026
Anathapindika Founder Speaks to Need for Detoxification in Supplementation: “Adding More Nutrients to Our Diets Is Not Enough for Healthy Living” Fort Lauderdale, FL, April 09, 2026 (GLOBE NEWSWIRE) -- The presence of [...]
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
09/04/2026
MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
09/04/2026
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groups Azenosertib therapeutic profile [...]

Pages